Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$109.84

-4.71 (-4.11%)

06:50
07/12/19
07/12
06:50
07/12/19
06:50

Eli Lilly announces presentation of post-hoc analyses from Emgality studies

Eli Lilly announced the presentation of post-hoc analyses showing improvements in daily functioning and reductions in disability in patients with chronic and episodic migraine treated with Emgality compared to placebo. The analyses are based on data from three double-blind, placebo-controlled, Phase 3 pivotal studies of Emgality in chronic and episodic migraine. The data will be presented at the American Headache Society, or AHS. Greater and statistically significant proportions of patients treated with Emgality showed reductions in disability due to migraine, as measured by the Migraine Disability Assessment, or MIDAS, when compared to placebo. The MIDAS questionnaire measures headache-related disability as lost time due to headache from paid work or school, household work and nonwork activities. The MIDAS disability categories correspond to different levels of limitation and medical need. Among patients in the chronic migraine pivotal study REGAIN, a statistically significant increase of 46.2% was seen in the proportion of patients with "little/no disability" after three months of treatment with Emgality compared to placebo, regardless of baseline disability. In the pooled analysis of the pivotal studies for episodic migraine EVOLVE-1 and EVOLVE-2, patients with "moderate to very severe disability" at baseline were 66.1% more likely to shift to "little/no disability" after six months of treatment with Emgality compared with placebo, with the difference achieving statistical significance. Treatment with Emgality was associated with improvements across all seven items of the Migraine-Specific Quality of Life Questionnaire Role Function-Restrictive Domain, or MSQ-RFR). The MSQ-RFR questionnaire measures the degree to which migraine limits a person's daily social and work-related activities, including: feeling more energetic; feeling less tired for work or daily activities; concentrating better on work/daily activities; able to get more done at work and home; less difficulty performing work/daily activities; less interference in leisure activities and less interference dealing with family and friends. In the REGAIN pivotal study for chronic migraine, patient gains in daily functioning were greater among patients treated with Emgality compared to placebo, for all items of the MSQ-RFR, with most reaching statistical significance. In the pooled analysis of the pivotal studies for episodic migraine patient gains in daily functioning were statistically significantly greater among patients treated with Emgality as compared to placebo across all seven items of MSQ-RFR. Overall, the analyses showed that patients treated with Emgality for the prevention of chronic or episodic migraine showed improvements in migraine-related disability and functional gains in the performance of daily activities that are limited by migraine.

  • 30

    Jul

  • 09

    Sep

  • 16

    Sep

  • 02

    Oct

LLY Eli Lilly
$109.84

-4.71 (-4.11%)

05/30/19
WELS
05/30/19
NO CHANGE
WELS
U.S. generic data continues to show challenging environment, says Wells Fargo
Wells Fargo analyst David Maris says that according to April IQVIA data, Teva (TEVA) U.S. generic sales were down 19% in April year over year, while brands sales were down 15%. Additionally, according to IQVIA data, Teva recently ceded its second place U.S. prescription market share place to competitor Eli Lilly (LLY) for its migraine drug, Ajovy, he points out. For Mylan (MYL), Maris says the monthly trends also paint a negative picture, with IQVIA U.S. generic sales in April down 36%. Nonetheless, the analyst believes Teva and Mylan shares seem to be reflecting an "aggressively negative outlook" given the current earnings multiples, and setting aside the worst-case outcomes in the opioid and price fixing cases, these may be at or nearing attractive valuations. However, for now, he remains on the sidelines, and within generics, continues to recommend Outperform-rated Amphastar (AMPH).
06/11/19
LEHM
06/11/19
UPGRADE
LEHM
Equal Weight
Novo Nordisk upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Novo Nordisk (NVO) to Equal Weight from Underweight and raised his price target for the shares to 325 kronor from 275 kronor. The analyst views competitor updates at the American Diabetes Association conference, specifically from Eli Lilly (LLY), as "underwhelming."
06/11/19
JPMS
06/11/19
NO CHANGE
JPMS
Overweight
Eli Lilly Rewind data missed 'fairly high' expectations, says JPMorgan
JPMorgan analyst Chris Schott is not surprised by the weakness yesterday in shares of Eli Lilly as he believes the Rewind data came in below "fairly high" expectations. However, the analyst ultimately sees the data confirming a cardiovascular benefit for Trulicity and supporting "continued strong Trulicity/GLP-1 uptake." Further, Schott sees the tirzepatide data at the American Diabetes Association conference as continuing to highlight a potentially best in class efficacy profile for the product. Lilly remains the analyst's top pick in his pharma coverage.
07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

BA

Boeing

$377.34

16.17 (4.48%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

16:24
07/19/19
07/19
16:24
07/19/19
16:24
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks were tentatively…

BA

Boeing

$377.34

16.17 (4.48%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

AAPL

Apple

$202.62

-3.02 (-1.47%)

WMT

Walmart

$113.91

-0.77 (-0.67%)

DIS

Disney

$139.86

-1.76 (-1.24%)

GCI

Gannett

$9.43

1.53 (19.37%)

CRWD

Crowdstrike

$83.50

10.75 (14.78%)

SKX

Skechers

$39.00

4.25 (12.23%)

PACB

Pacific Biosciences

$5.34

-0.53 (-9.03%)

ILMN

Illumina

$293.10

-5.44 (-1.82%)

CHWY

Chewy

$30.70

-2.09 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 15

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/19/19
07/19
16:20
07/19/19
16:20
Options
Closing CBOE SPX and VIX Index summary for July 19th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/19/19
07/19
16:17
07/19/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCBP

BCB Bancorp

$12.71

-0.09 (-0.70%)

16:17
07/19/19
07/19
16:17
07/19/19
16:17
Earnings
BCB Bancorp reports Q2 EPS 30c, consensus 30c »

Net interest margin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNXM

CNX Midstream Partners

$14.30

-0.205 (-1.41%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Hot Stocks
CNX Midstream Partners raises quarterly distribution 3.6% to 38.65c per unit »

CNX Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

TELL

Tellurian

$7.25

0.22 (3.13%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Syndicate
Breaking Syndicate news story on Tellurian »

Tellurian files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
07/19/19
07/19
16:15
07/19/19
16:15
General news
Breaking General news story  »

Boston Federal Reserve…

ROKU

Roku

$106.83

-2.18 (-2.00%)

16:13
07/19/19
07/19
16:13
07/19/19
16:13
Conference/Events
Roku management to meet with Oppenheimer »

Bull/Bear Luncheon to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 07

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.